

Lumito AB and Katana Labs GmbH sign Letter of Intent and enter into a strategic partnership to enhance biomarker detection and quantification

Lumito AB (publ) ("Lumito" or the "Company") today announces that the Company and Katana Labs GmbH ("Katana Labs") have signed a Letter of Intent ("LOI") formalising a strategic partnership to jointly commercialise an end-to-end, ultra-sensitive immunohistochemistry (IHC) workflow that integrates Lumito's labelling and scanning technology with Katana Labs' AI-powered image analysis platform. This is a result of the first phase of the collaboration, which was successful, after which the companies now strengthen the commercial collaboration.

"We are excited that we are taking concrete steps towards offering a plug-and-play IHC workflow solution that includes Lumito's SCIZYS system and Katana Labs' cloud-native software for AI-powered image analysis and quantification. This will enable our customers to address challenging research questions with a powerful and integrated solution," says Sanna Wallenborg, CEO of Lumito.

Lumito and Katana Labs will develop and jointly commercialise an end-to-end, ultra-sensitive immunohistochemistry (IHC) workflow that integrates Lumito's up-converting nanoparticle (UCNP)-based imaging technology with Katana Labs' advanced AI-powered image analysis platform. The strategic collaboration aims to deliver a fully integrated ultra-sensitive IHC platform for enhanced tissue analysis and reliable biomarker detection, addressing critical unmet research needs in IHC e.g. the detection and quantification of low/ultralow expressed biomarkers such as HER2. Users can implement the end-to-end workflow in-house or access it as scanning-as-a-service.

"This partnership brings together two highly complementary technologies that, together, redefine what's possible in reliable and robust biomarker detection. By uniting Lumito's physical detection sensitivity with Katana Labs' computational intelligence, we are setting a new benchmark for precision oncology and translational research," says Dr. Norman Gerstner, Chief Business Officer at Katana Labs.

The LOI precedes a non-exclusive agreement under which both parties will continue their independent commercial activities. At the same time, they will collaborate to further validate and promote their combined end-to-end workflow through co-marketing and joint commercialisation efforts. By presenting each other's solutions in customer meetings and shared presentations, both companies aim to expand market exposure and provide CRO and biopharma R&D customers with an integrated, all-in-one workflow solution, from labeling kit to scanner and cloud-based image analysis.

For further information, please contact:

Sanna Wallenborg, CEO Lumito
E-mail: sw@lumito.se
Ph: +4670-870 01 68

About Katana Labs

Katana Labs is a software engineering and artificial intelligence (AI) company that builds AI-powered and cloud-native software to decode biology in the context of complex diseases. Katana Labs develops best-in-class deep learning models for the automated analysis of large image datasets. These models are designed to meet the specific needs of various applications in advanced histopathology and tissue analysis, including accurate cell segmentation, biomarker quantification, and multidimensional data extraction. Made readily available through Katana Labs' cloud platform, R&D teams can easily explore, analyse, and collaborate on whole slide images and tissue microarrays directly via a browser-based interface. By automating time-consuming processing, segmentation, and bioinformatics tasks, Katana Labs' AI platform enables researchers and clinical scientists to enhance workflow efficiency and productivity.

About Lumito

Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. www.lumito.se/en/

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

Attachments

[Lumito AB and Katana Labs GmbH sign Letter of Intent and enter into a strategic partnership to enhance biomarker detection and quantification](#)